Increasing small intestinal permeability worsens colitis in the IL-10-/- mouse and prevents the induction of oral tolerance to Ovalbumin

Inflammatory Bowel Diseases

Volumn 21, Issue 1, 2015, Pages 8-18

  Arrieta, Marie Claire ^a   Madsen, Karen L ^b   Field, Catherine J ^b   Meddings, Jonathan B ^c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

AT 1002; Colitis; IL 10 gene deficient mouse; Intestinal permeability; Oral tolerance

Indexed keywords

AGENTS USED IN INFLAMMATORY BOWEL DISEASE; AT 1002; CD11B ANTIGEN; CD8 ANTIGEN; GLYCOPROTEIN P 15095; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; INTERLEUKIN 5; OVALBUMIN; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; AT1002; IL10 PROTEIN, MOUSE; OLIGOPEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL EXPANSION; CELL PROLIFERATION; COLITIS; COLON MUCOSA; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOKINE RESPONSE; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG MEGADOSE; EX VIVO STUDY; HUMORAL IMMUNITY; IMMUNOLOGICAL TOLERANCE; INTESTINE MUCOSA PERMEABILITY; LOW DRUG DOSE; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SMALL INTESTINAL PERMEABILITY; SMALL INTESTINE; SPLEEN CELL; TIGHT JUNCTION; WILD TYPE; ANIMAL; CELL MEMBRANE PERMEABILITY; DISEASE MODEL; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOLOGY; PHYSIOLOGY;

ADMINISTRATION, ORAL; ANIMALS; CELL MEMBRANE PERMEABILITY; COLITIS; DISEASE MODELS, ANIMAL; IMMUNE TOLERANCE; INTERLEUKIN-10; INTESTINE, SMALL; MICE; MICE, KNOCKOUT; OLIGOPEPTIDES; OVALBUMIN;

EID: 84925709065     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000253     Document Type: Article

References (34)

1. Kennedy RJ, Hoper M, Deodhar K, et al. Interleukin 10-deficient colitis: new similarities to human inflammatory bowel disease. Br J Surg. 2000; 87:1346-1351.
2. Madsen KL, Malfair D, Gray D, et al. Interleukin-10 gene-deficient mice develop a primary intestinal permeability defect in response to enteric microflora. Inflamm Bowel Dis. 1999;5:262-270.
3. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001;411: 603-606.
4. Peltekova VD, Wintle RF, Rubin LA, et al. Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nat Genet. 2004;36:471-475.
5. Rioux JD, Xavier RJ, Taylor KD, et al. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet. 2007;39:596-604.
6. Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 2006; 314:1461-1463.
7. Olson TS, Reuter BK, Scott KG, et al. The primary defect in experimental ileitis originates from a nonhematopoietic source. J Exp Med. 2006;203: 541-552.
8. Resta-Lenert S, Smitham J, Barrett KE. Epithelial dysfunction associated with the development of colitis in conventionally housed mdr1a-/- mice. Am J Physiol Gastrointest Liver Physiol. 2005;289:G153-G162.
9. Arrieta MC, Madsen K, Doyle J, et al. Reducing small intestinal permeability attenuates colitis in the IL10 gene-deficient mouse. Gut. 2009;58: 41-48.
10. Soderholm JD, Olaison G, Peterson KH, et al. Augmented increase in tight junction permeability by luminal stimuli in the non-inflamed ileum of Crohn's disease. Gut. 2002;50:307-313.
11. Katz KD, Hollander D, Vadheim CM, et al. Intestinal permeability in patients with Crohn's disease and their healthy relatives. Gastroenterology. 1989;97:927-931.
12. Rizzo LV, Morawetz RA, Miller-Rivero NE, et al. IL-4 and IL-10 are both required for the induction of oral tolerance. J Immunol. 1999;162: 2613-2622.
13. Munkholm P, Langholz E, Hollander D, et al. Intestinal permeability in patients with Crohn's disease and ulcerative colitis and their first degree relatives. Gut. 1994;35:68-72.
14. Gopalakrishnan S, Pandey N, Tamiz AP, et al. Mechanism of action of ZOT-derived peptide AT-1002, a tight junction regulator and absorption enhancer. Int J Pharm. 2009;365:121-130.
15. Paterson BM, Lammers KM, Arrieta MC, et al. The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study. Aliment Pharmacol Ther. 2007;26:757-766.
16. Faria AM, Weiner HL. Oral tolerance. Immunol Rev. 2005;206:232-259.
17. Wiedermann U. Mucosal immunity-mucosal tolerance. A strategy for treatment of allergic diseases. Chem Immunol Allergy. 2003;82:11-24.
18. Faria AM, Maron R, Ficker SM, et al. Oral tolerance induced by continuous feeding: enhanced up-regulation of transforming growth factor-beta/ interleukin-10 and suppression of experimental autoimmune encephalomyelitis. J Autoimmun. 2003;20:135-145.
19. Pabst O, Mowat AM. Oral tolerance to food protein. Mucosal Immunol. 2012;5:232-239.
20. Hornef MW, Putsep K, Karlsson J, et al. Increased diversity of intestinal antimicrobial peptides by covalent dimer formation. Nat Immunol. 2004; 5:836-843.
21. Neutra MR, Frey A, Kraehenbuhl JP. Epithelial M cells: gateways for mucosal infection and immunization. Cell. 1996;86:345-348.
22. Fujita M, Reinhart F, Neutra M. Convergence of apical and basolateral endocytic pathways at apical late endosomes in absorptive cells of suckling rat ileum in vivo. J Cell Sci. 1990;97(pt 2):385-394.
23. Kaiserlian D, Vidal K, Revillard JP. Murine enterocytes can present soluble antigen to specific class II-restricted CD4+ T cells. Eur J Immunol. 1989;19:1513-1516.
24. Rescigno M, Urbano M, Valzasina B, et al. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat Immunol. 2001;2:361-367.
25. Zhang ZY, Michael JG. Orally inducible immune unresponsiveness is abrogated by IFN-gamma treatment. J Immunol. 1990;144:4163-4165.
26. Andrade MC, Menezes JS, Cassali GD, et al. Alcohol-induced gastritis prevents oral tolerance induction in mice. Clin Exp Immunol. 2006;146: 312-322.
27. Garside P, Mowat AM. Oral tolerance. Semin Immunol. 2001;13: 177-185.
28. Dubois B, Goubier A, Joubert G, et al. Oral tolerance and regulation of mucosal immunity. Cell Mol Life Sci. 2005;62:1322-1332.
29. Kraus TA, Toy L, Chan L, et al. Failure to induce oral tolerance to a soluble protein in patients with inflammatory bowel disease. Gastroenterology. 2004;126:1771-1778.
30. Duchmann R, May E, Heike M, et al. T cell specificity and cross reactivity towards enterobacteria, bacteroides, bifidobacterium, and antigens from resident intestinal flora in humans. Gut. 1999;44:812-818.
31. Duchmann R, Neurath MF, Meyer zum Buschenfelde KH. Responses to self and non-self intestinal microflora in health and inflammatory bowel disease. Res Immunol. 1997;148:589-594.
32. Knoflach P, Park BH, Cunningham R, et al. Serum antibodies to cow's milk proteins in ulcerative colitis and Crohn's disease. Gastroenterology. 1987;92:479-485.
33. Watts T, Berti I, Sapone A, et al. Role of the intestinal tight junction modulator zonulin in the pathogenesis of type I diabetes in BB diabeticprone rats. Proc Natl Acad Sci U S A. 2005;102:2916-2921.
34. Jarvinen KM, Konstantinou GN, Pilapil M, et al. Intestinal permeability in children with food allergy on specific elimination diets. Pediatr Allergy Immunol. 2013;24:589-595.